MedTrace Logo

Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease

NCT02405598 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-09-20

No results posted yet for this study

Summary

evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset Pompe disease under enzyme replacement therapy

Conditions

  • Pompe Disease

Interventions

DRUG

Salbutamol

1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot) 2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yin-Hsiu Chien, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-07-31
Completion
2016-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02405598 on ClinicalTrials.gov